We use cookies for a better user experience. Read our Privacy Policy

I Agree

Rise in the Initiatives by Non-governmental and Governmental Agencies to Better Understanding of Multiple Sclerosis to Drive Global Multiple Sclerosis Drugs Market

Pharmaceutical |

Government as well as non-government groups are promoting the understanding of the condition and thus are likely to encourage growth of the global multiple sclerosis drugs market. The government and non-governmental groups support a range of efforts and programmes to help people with multiple sclerosis improve their quality of life. The World Health Organization (WHO) produced an Essential Medicines List (EML) in 2020, as there are now no medications on the EML that are used to treat multiple sclerosis (MS). In conjunction with the World Federation of Neurology and the Regional Committees for Treatment and Research in Multiple Sclerosis (TRIMS), the Multiple Sclerosis International Federation (MSIF) had produced a proposal in& the 2019 EML that included disease-modifying medicines for MS.

Some prominent players that are found in the global multiple sclerosis drugs market include companies such as Actelion Pharmaceuticals (Johnson & Johnson), F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., EMD Serono (Merck KGaA), Celgene Corporation, and Bayer AG

The global multiple sclerosis drugs market is projected to expand at a CAGR of 5.9% during the forecast period, from 2017 to 2027. The huge increase in the number of research projects concentrating on the identification of novel multiple sclerosis medications with increased effectiveness is largely responsible for the expansion of the global multiple sclerosis drugs market. Stakeholders need to concentrate on getting FDA clearance for their newly developed multiple sclerosis treatments while also pursuing mergers and acquisitions to expand their presence in the existing multiple sclerosis drugs market. Stakeholders should also concentrate on optimizing their distribution networks and exploring market prospects in e-Commerce platforms.

Increased Sale of MS Medications to Drive Growth of the North America Market

Geographical classifications are expected to give a better understanding of the market forces at play at the regional level.

North America is expected to lead the global multiple sclerosis drugs market in terms of revenue throughout the forecast period, from 2019 to 2027. This is due to increased sales of multiple sclerosis medications in nations like Canada and the U.S. Furthermore, the North America market is driven by an increase in the incidence of multiple sclerosis in the area as well as advantageous medical reimbursement policies in the U.S. and Canada. The multiple sclerosis drugs market in Asia Pacific, on the other hand, is predicted to grow at a comparatively high growth rate over the forecast period. The market in Asia Pacific is likely to be fueled by a huge pool of multiple sclerosis patients in Japan and China, as well as the approval and introduction of new treatments. In addition, the approval and introduction of new medications, as well as increased investments by major regional companies in therapeutic medications for multiple sclerosis illness, is estimated to boost the market in Asia Pacific.

Rise in the Incidence of MS Globally to Spell Growth for the Market

Major drivers responsible for the growth of the global multiple sclerosis drugs market include an increase in the occurrence of multiple sclerosis, and more knowledge about multiple sclerosis. A massive rise in the elderly population leading to an increase in instances of multiple sclerosis is also expected to drive market. Multiple sclerosis is a condition of the central nervous system. It is a spinal cord and brain condition that has the potential to be devastating. The immune system assaults the myelin (protective coating) that surrounds nerve fibers in multiple sclerosis, causing communication problems between the brain and other parts of the human body. Multiple sclerosis can produce nerve loss or degeneration that is irreversible. The reason for multiple sclerosis is still not known. Multiple sclerosis is believed to be caused by a combination of hereditary as well as environmental factors.

Despite the fact that there is no real remedy for multiple sclerosis, new drugs to reduce the disease's course and treat symptoms are becoming more popular. Research and development is now playing an important role in the creation of innovative therapies. Disease-modifying therapies (DMTs) have traditionally been the most common kind of medicine used to treat multiple sclerosis. Companies in the global multiple sclerosis drugs market are concentrating their efforts on obtaining FDA clearance for their newly produced treatments.

The information provided in the review has been extracted from a TMR report titled “Multiple Sclerosis Drugs Market (Drug Class: Interferon Beta, Sphingosine 1 Phosphate Receptor Modulators, Mixed Polymers, NF-KB Inhibitor, Pyrimidine Synthesis Inhibitor, Monoclonal Antibodies, Corticosteroids, Adrenocorticotropic Hormone, and Others; Disease Type: Relapsing-remitting MS (RRMS), Primary-progressive MS (PPMS), Secondary-progressive MS (SPMS), and Progressive-relapsing MS (PRMS); Route of Administration: Parenteral and Oral; and Distribution Channel: Hospital Pharmacies, Retail Pharmacies & Drug Stores, and Online Pharmacies) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019 - 2027”.

The global Multiple Sclerosis Drugs market is segmented based on:

Drug Class

  • Interferon Beta
  • Sphingosine 1 Phosphate Receptor Modulators
  • Mixed Polymers, NF-KB Inhibitor
  • Pyrimidine Synthesis Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Adrenocorticotropic Hormone

Disease Type

  • Relapsing-remitting MS (RRMS)
  • Primary-progressive MS (PPMS)
  • Secondary-progressive MS (SPMS)
  • Progressive-relapsing MS (PRMS)

Route of Administration

  • Parenteral
  • Oral

Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies & Drug Stores
  • Online Pharmacies


  • Latin America
  • North America
  • Europe
  • Japan
  • Asia Pacific excluding Japan
  • Middle East and Africa

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through adhoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.”


Transparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com

Copyright © Transparency Market Research, Inc. All Rights reserved